George Yancopoulos, Regeneron president and CSO (courtesy Regeneron)
August 15, 2023 08:25 AM EDT
People
R&D

Ex­clu­sive: CSO George Yan­copou­los talks Re­gen­eron’s next chap­ter of ge­net­ics, weight loss drugs, and Alzheimer's

Andrew Dunn

Senior Biopharma Correspondent

TAR­RY­TOWN, NY — Thir­ty-five years since they found­ed Re­gen­eron, the two out­spo­ken New York­ers atop the com­pa­ny are look­ing be­yond its vaunt­ed an­ti­body ex­per­tise as they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times